FDA approves Merck's RSV prevention drug for infants

Merck (MRK) received FDA approval for ENFLONSIA™ (clesrovimab-cfor), a monoclonal antibody for RSV prevention in newborns and infants, demonstrating a 60.5% reduction in RSV-associated lower respiratory infections and an 84.3% reduction in hospitalizations compared to placebo. The single-dose, non-weight-based drug is expected to be available in the U.S. before the 2025-2026 RSV season. This approval comes amid other developments for Merck, including positive Phase 3 results for its cholesterol drug enlicitide decanoate and potential acquisition talks with MoonLake Immunotherapeutics, while analyst ratings remain mixed.

Analysis

Merck & Co. has secured a significant regulatory milestone with the U.S. Food and Drug Administration's approval of ENFLONSIA™ (clesrovimab-cfor), a monoclonal antibody designed for the prevention of respiratory syncytial virus (RSV) in newborns and infants. This approval is substantiated by robust efficacy data from the Phase 2b/3 CLEVER trial, which demonstrated a 60.5% reduction in RSV-associated medically attended lower respiratory infections and an 84.3% decrease in RSV-associated hospitalizations compared to placebo. A key innovation is ENFLONSIA's single 105 mg non-weight-based dosing, a first for infant RSV prevention options, simplifying administration. The drug, with a safety profile comparable to palivizumab as shown in the Phase 3 SMART trial, is slated for U.S. availability before the 2025-2026 RSV season. This launch is poised to contribute to Merck's substantial annual revenues of $63.92 billion and its impressive 77.07% gross profit margin. Further strengthening Merck's pipeline, the company reported successful Phase 3 trial results for its cholesterol drug, enlicitide decanoate, which could become the first oral PCSK9 inhibitor in the U.S. if approved. Strategically, Merck is also reportedly exploring an acquisition of MoonLake Immunotherapeutics for over $3 billion to enhance its drug portfolio, although an initial offer was declined. Analyst perspectives are somewhat divergent: BMO Capital maintains a Market Perform rating, acknowledging potential short-term challenges despite a promising long-term oncology strategy, whereas Goldman Sachs reaffirms a Buy rating, highlighting Merck's expansive oncology strategy and a potential commercial opportunity exceeding $25 billion by the mid-2030s.

Key Decisions for Investors

• Merck's recent FDA approval for ENFLONSIA and positive Phase 3 data for enlicitide decanoate signal a strengthening product pipeline, supporting a positive outlook for the company's future revenue growth.
• Investors should monitor Merck's strategic M&A activities, such as the pursuit of MoonLake Immunotherapeutics, as successful acquisitions could significantly enhance its drug pipeline and long-term value proposition.
• Despite a strong long-term therapeutic outlook, particularly in oncology, it is prudent to consider the mixed analyst ratings and watch for any emerging short-term operational challenges or delays in pipeline execution.
• For those tracking MoonLake Immunotherapeutics, the reported acquisition interest from a major pharmaceutical entity like Merck, even if initially rebuffed, underscores its potential strategic value and could signal future corporate actions or valuation uplifts.